Publicacións en colaboración con investigadores/as de Eli Lilly and Company (3)

2022

  1. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810